Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Myeloproliferative Disorders 1

Interventions

Cyclophosphamide 15fludarabine phosphate 12Filgrastim 10Peripheral Blood Stem Cell Transplantation 9ruxolitinib 8Decitabine 8fludarabine 7Tacrolimus 7Etoposide 7Melphalan 6Cytarabine 6Azacitidine 6Vorinostat 5Mycophenolic Acid 5Ipilimumab 5venetoclax 4Specimen Handling 4Sirolimus 4Idarubicin 4Granulocyte Colony-Stimulating Factor 4ivosidenib 3fedratinib 3aldesleukin 3Whole-Body Irradiation 3Rituximab 3Radiotherapy 3Nivolumab 3Methylprednisolone 3Imatinib Mesylate 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Myeloproliferative Disorders × LY2784544 × Clear all
NCT01134120 2018-04-17

A Study in Myeloproliferative Disorders

Eli Lilly and Company

Phase 1 Completed
80 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡